New England Journal of Medicine· 2016Q1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- 1,516citations
- Q1SCImago
- 2016year
Short summary
Adding daratumumab to bortezomib and dexamethasone significantly improved progression-free survival (PFS) in relapsed/refractory multiple myeloma patients, with a median PFS not reached vs. 7.2 months in the control arm.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine